Author:
Gong Linna,Miao Zhishuo,Zhang Li,Shi Birui,Xiao Zuoqi,Qiu Panzi,Liu Menghua,Zou Wei
Abstract
Abstract
Background
Penyanqing (PYQ), a traditional Chinese medicine (TCM), has a good clinical efficacy for the treatment of pelvic inflammatory disease (PID). Previously, researches on its anti-inflammatory effect and mechanism in vitro, in silico, and in vivo have been reported by our team. However, the interrelationship between the anti-inflammatory activity and the active compounds in PYQ are not clear. Here, the pharmacokinetics-pharmacodynamics (PK-PD) study was carried out for more proper clinical use.
Methods
The plasma concentrations of salvianolic acid B (SAB), protocatechualdehyde (PRO), paeoniflorin (PE), astilbin (AST), ferulic acid (FE), and chlorogenic acid (CH) in SD rats after PYQ administration were determined by a selective and rapid HPLC–MS/MS method. In addition, the PK-PD on cell model was used to explore the relationship between the plasma concentration and inflammatory biomarkers (TNF-α, IL-1β).
Results
The results of this study showed that the six components could reach the peak blood concentration within 0.29 h, indicating the rapid absorption of it. The eliminations of AST, CH, FE, PE, and PRO were relatively fast due to their mean residence times (MRTs) within 3 h, while the elimination of SAB was slower (MRT 5.67 ± 0.66 h). Combined with a THP-1 cell model, there was a significant correlation between inflammatory factors and component plasma concentrations with correlation coefficients in the range of -0.9—-0.746. Correspondingly, the drug-containing plasma obtained at 0.25 h point exhibited the best inhibition effect on production of IL-1β and TNF-α in LPS-induced THP-1 cells.
Conclusion
The six main components in PYQ could be quickly absorbed, and there was a potential good correlation between their pharmacokinetics and the pharmacodynamics of PYQ.
Funder
Hunan Provincial Science and Technology Department
Publisher
Springer Science and Business Media LLC
Subject
Complementary and alternative medicine
Reference34 articles.
1. Ford GW, Decker C. Pelvic inflammatory disease. Dis Mon. 2016;62(8):301–5.
2. Wang Y, Wang D. Clinical research progress of TCM in treating pelvic inflammatory disease. Chin J Ethno. 2016;25(01):34–5.
3. Zou W, Wen X, Hu J, Xiao Z, Zheng Y. Pharmacological effects of Penyanling mixture in rats with chronic pelvic inflammatory diseases. Chin J Hosp. 2017;37(14):1339–42.
4. Zhang X. 102 cases of pelvic inflammatory disease treated with Penyanling. Chin J Integr Tradit West Med. 1988;07:440.
5. Xiao Z, Pan T, Ouyang B, Huang Y, Tian X, Wen X. HPLC fingerprints of Penyanling granules. Chin J New Drugs. 2015;24(16):1897–901.